share_log

和鉑醫藥-B：正面盈利警告

HBM HOLDINGS-B: POSITIVE PROFIT ALERT

香港交易所 ·  Jan 18 23:00
Summary by Moomoo AI
和铂医药-B（02142）发布正面盈利警告，预告2023年全年将录得约1800万美元溢利，相较于2022年约1.37亿美元的亏损，实现扭亏为盈。这一转变主要得益于提高业务运营效率、改善成本控制以及Harbour Therapeutics产品组合中创新产品如HBM7008及HBM9161的授权和合作所带来的收入增长。此外，与全球制药公司的战略合作，如HBM9033的开发和商业化，以及諾納生物持续的全球产业及业务发展势头，均显著推动了收入增长。公司董事会提醒股东及潛在投資者，上述财务数据为初步评估，未经审计，实际业绩可能与公告所披露的数据有所不同，故不应作为投资依据。公司将于2024年3月底前发布经审计的全年业绩。
和铂医药-B（02142）发布正面盈利警告，预告2023年全年将录得约1800万美元溢利，相较于2022年约1.37亿美元的亏损，实现扭亏为盈。这一转变主要得益于提高业务运营效率、改善成本控制以及Harbour Therapeutics产品组合中创新产品如HBM7008及HBM9161的授权和合作所带来的收入增长。此外，与全球制药公司的战略合作，如HBM9033的开发和商业化，以及諾納生物持续的全球产业及业务发展势头，均显著推动了收入增长。公司董事会提醒股东及潛在投資者，上述财务数据为初步评估，未经审计，实际业绩可能与公告所披露的数据有所不同，故不应作为投资依据。公司将于2024年3月底前发布经审计的全年业绩。
Platinum Pharmaceuticals-B (02142) issued a positive profit warning, projecting a profit of about $1800 million in 2023, compared with a loss of about $1.37 million in 2022, a reversal in profits. This transformation is primarily driven by increased business efficiency, improved cost control, and increased revenue from the licensing and collaboration of innovative products such as HBM7008 and HBM9161 in the Harbor Therapeutics portfolio. In addition, strategic partnerships with global pharmaceutical companies, such as the development and commercialization of HBM9033, as well as Nona Biologicals' ongoing global industry and business development, have significantly driven revenue growth. The Board of Directors reminds shareholders and potential investors that the above financial data are preliminary estimates, unaudited, and that the actual performance may differ from the information disclosed in the announcement and should therefore not be used as investment data. The company will publish the annual results of the audit by the end of March 2024.
Platinum Pharmaceuticals-B (02142) issued a positive profit warning, projecting a profit of about $1800 million in 2023, compared with a loss of about $1.37 million in 2022, a reversal in profits. This transformation is primarily driven by increased business efficiency, improved cost control, and increased revenue from the licensing and collaboration of innovative products such as HBM7008 and HBM9161 in the Harbor Therapeutics portfolio. In addition, strategic partnerships with global pharmaceutical companies, such as the development and commercialization of HBM9033, as well as Nona Biologicals' ongoing global industry and business development, have significantly driven revenue growth. The Board of Directors reminds shareholders and potential investors that the above financial data are preliminary estimates, unaudited, and that the actual performance may differ from the information disclosed in the announcement and should therefore not be used as investment data. The company will publish the annual results of the audit by the end of March 2024.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more